We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
167 result(s) found, displaying 41 to 50
-
Australian public assessment report (AusPar)Esperoct (turoctocog alfa pegol) has been approved to prevent or reduce the frequency of bleeding episodes in patients with haemophilia A.
-
Prescription medicine decision summaryAlhemo (concizumab) is approved to prevent haemophilia.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEGOVY 1.7 mg semaglutide 2.27 mg/mL solution for injection pre-filled pen with pre-assembled needle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEGOVY 2.4 mg semaglutide 3.2 mg/mL solution for injection pre-filled pen with pre-assembled needle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEGOVY 0.25 mg semaglutide 0.5 mg/mL solution for injection pre-filled pen with pre-assembled needle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEGOVY 1 mg semaglutide 2.0 mg/mL solution for injection pre-filled pen with pre-assembled needle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEGOVY 0.5 mg semaglutide 1.0 mg/mL solution for injection pre-filled pen with pre-assembled needle.
-
Prescription medicine registrationActive ingredients: somapacitan.
-
Prescription medicine registrationActive ingredients: concizumab.
-
Prescription medicine decision summaryTGA decision: Alhemo is approved where prophylaxis is required to prevent or reduce the frequency of bleeding in patients at least 12 years of age who have haemophilia B.